Amneal Pharmaceuticals Operating Income

Amneal Pharmaceuticals posts a operating income of $-220M as of June 2026. That compares with $380M in the prior-year period — down 158.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Amneal Pharmaceuticals's operating income was $380M. The latest reading is $-220M — a 158.0% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Amneal Pharmaceuticals's financial statement story. At $-220M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AMRX's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Amneal Pharmaceuticals's other metric pages and overview cover the third.

Judging Amneal Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-220M here, then scan peer and history charts to see if the gap is persistent.